Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
NCT ID: NCT00759382
Last Updated: 2021-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
340 participants
OBSERVATIONAL
2008-07-31
2022-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma
NCT06833229
Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up
NCT00198341
Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer
NCT05260606
Value of F-18 FDG PET/CT for the Prediction of EGFR Mutation in Lung Cancer Patients
NCT06520189
Interest of CPET to Predict Mortality and Complications of Lung Resection Candidates
NCT05502263
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
I
Patients with non-small cell lung carcinoma treated with curative intent
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stage I-III treated by curative treatment by surgery with or without chemotherapy (induction or adjuvant) or by chemoradiotherapy
* Inoperable patients treated by exclusive radiotherapy
* A whole-body (skull base to mid thighs) FDG-PET or a combined FDG-PET/CT on a dedicated machine, performed before any anticancer treatment
* FDG-PET or combined FDG-PET/CT has to be previously standardised according to the procedure described in appendix IV
* Written informed consent
* Accessibility to follow-up
* Age \> 18 years
Exclusion Criteria
* Stage IV NSCLC
* A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix and cured malignant tumour (more than 5-year disease free interval)
* Uncontrolled diabetes mellitus (fast glycaemia above 130 mg/dl)
* Pregnancy and lactating woman
* Unavailability to send a copy of the PET or PET-CT (DICOM format) to the data centre
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Lung Cancer Working Party
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thierry Berghmans, MD
Role: STUDY_CHAIR
European Lung Cancer Working Party
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pneumology RHMS Hôpital de la Madeleine
Ath, , Belgium
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet
Brussels, , Belgium
Department of Pneumology CHU Charleroi
Charleroi, , Belgium
Department of Pneumology Hôpital Saint-Joseph
Gilly, , Belgium
Hôpital Ambroise Paré
Mons, , Belgium
Department of Pneumology Centre Hospitalier de Mouscron
Mouscron, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information on the protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01071
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.